The development of these molecules (PT2385 and PT2399) have may provide a therapeutic opportunity to perhaps successfully treat pharmacologically several types of cancers which currently have limited therapeutic options (e.g. patients with SDHB-related metastatic phaeochromocytoma/paraganglioma) (34). The gene discussed is SDHB; the disease is paraganglioma.